miR‑132 improves the cognitive function of rats with Alzheimer's disease by inhibiting the MAPK1 signal pathway

Deng, Yiming; Zhang, Jingyu; Sun, Xuan; Ma, Gaoting; Luo, Gang; Miao, Zhongrong; Song, Ligang

doi:10.3892/etm.2020.9288

Cited by 49 publications

(46 citation statements)

References 43 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuron apoptosis during AD is closely associated with the MAPK pathway ( Li et al, 2019 ). In the study by Deng et al (2020) miR-132 expression was significantly downregulated in an AD rat model, and MAPK1 expression was significantly upregulated; they suggested that miR-132 and MAPK1 had specific binding sites, and that miR-132 could inhibit MAPK1 expression. They concluded that miR-132 can inhibit hippocampal oxidative stress and iNOS expression by inhibiting MAPK1 expression to improve the cognitive function of AD rats ( Deng et al, 2020 ).…”

Section: Neuropathogenesis and Neuroprotection Of Mir-132 In Ad: Implications From In Vivo And In Vitro mentioning

confidence: 99%

Alzheimer’s Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target

Zhang

Bian

2021

Front. Neurosci.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a common neurodegenerative disease in the elderly and is the most common type of dementia. AD is mostly gradual onset, and involves slow, progressive mental decline, accompanied by personality changes; the incidence of AD gradually increases with age. The etiology of AD is unknown, although it is currently believed to be related to abnormal deposition of amyloid β-protein (Aβ) in the brain, hyperphosphorylation of microtubule-associated protein tau, and the release of various cytokines, complements, activators and chemokines by cells. MicroRNAs (miRNAs) are a class of highly conserved non-coding RNAs that regulate gene expression at the post-transcriptional level, and manipulate the functions of intracellular proteins and physiological processes. Emerging studies have shown that miRNA plays an important role in regulating AD-related genes. MiR-132 is known as “NeurimmiR” due to its involvement in numerous neurophysiological and pathological processes. Accumulating pre-clinical results suggest that miR-132 may be involved in the progression of Aβ and tau pathology. Moreover, clinical studies have indicated that decreased circulating miR-132 levels could be used a potential diagnostic biomarker in AD. Here, we review the pathogenic role of miR-132 activity in AD, and the potential of targeting miR-132 for developing future therapeutic strategies.

show abstract

Section: Neuropathogenesis and Neuroprotection Of Mir-132 In Ad: Implications From In Vivo And In Vitro mentioning

confidence: 99%

Alzheimer’s Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target

Zhang

Bian

2021

Front. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Tau phosphorylation can be modulated by some miRNAs, namely, miR-200a-3p, miR-326, miR-124-3p, miR-146a, miR-425-5p, and miR-132. Expression of miR-132 has been assessed by several investigations with most of them reporting its downregulation in AD (Wong et al, 2013 ; El Fatimy et al, 2018 ; Cha et al, 2019 ; Deng et al, 2020 ). Yet, Liu et al have reported over-expression of miR-132 in patients with mild cognitive impairment and AD vs. normal individuals (Liu and Zhang, 2019 ).…”

Section: Discussionmentioning

confidence: 99%

“…Experiments in a rat model of AD have shown upregulation of AChE, iNOS, ROS, MDA, MAPK1, and p-MAPK1 and downregulation of SOD, GSH-Px, and miR-132. Over-expression of miR-132 has reversed these markers demonstrating the role of this miRNA in the suppression of hippocampal iNOS expression and oxidative stress through reduction of MAPK1 levels (Deng et al, 2020 ). However, expression of this miRNA has been demonstrated to be reduced in neurally-originated plasma exosomes of AD subjects (Cha et al, 2019 ).…”

Section: Dysregulated Mirnas In Admentioning

confidence: 99%

“…Although several studies have reported downregulation of miR-132 in AD (Wong et al, 2013 ; El Fatimy et al, 2018 ; Cha et al, 2019 ; Deng et al, 2020 ), Liu et al have reported high levels of miR-132 in patients with mild cognitive impairment and AD vs. normal individuals. They have shown the impact of miR-132 upregulation in the induction of apoptosis in neurons through increasing Bax/Bcl-2 ratio (Liu and Zhang, 2019 ).…”

Section: Dysregulated Mirnas In Admentioning

confidence: 99%

See 1 more Smart Citation

The Eminent Role of microRNAs in the Pathogenesis of Alzheimer's Disease

Samadian

Gholipour

Hajiesmaeili

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

Alzheimer's disease (AD) is an irrevocable neurodegenerative condition characterized by the presence of senile plaques comprising amassed β-amyloid peptides (Aβ) and neurofibrillary tangles mainly comprising extremely phosphorylated Tau proteins. Recent studies have emphasized the role of microRNAs (miRNAs) in the development of AD. A number of miRNAs, namely, miR-200a-3p, miR-195, miR-338-5p, miR-34a-5p, miR-125b-5p, miR-132, miR-384, miR-339-5p, miR-135b, miR-425-5p, and miR-339-5p, have been shown to participate in the development of AD through interacting with BACE1. Other miRNAs might affect the inflammatory responses in the course of AD. Aberrant expression of several miRNAs in the plasma samples of AD subjects has been shown to have the aptitude for differentiation of AD subjects from healthy subjects. Finally, a number of AD-modifying agents affect miRNA profile in cell cultures or animal models. We have performed a comprehensive search and summarized the obtained data about the function of miRNAs in AD in the current review article.

show abstract

“…Number of article Route of Administration ICV IP Oral Sub-cutaneous Amyloid β** 35 [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34]. [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47] 35 0 0 0 Streptozotocin** 16 [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63] 16...…”

Section: Toxic Substancesmentioning

confidence: 99%

Toxic Substance-induced Hippocampal Neurodegeneration in Rodents as Model of Alzheimer’s Dementia

Nurmasitoh

Sari

Susilowati

2021

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Alzheimer’s Dementia (AD) cases are increasing with the global elderly population. To study the part of the brain affected by AD, animal models for hippocampal degeneration are still necessary to better understand AD pathogenesis and develop treatment and prevention measures. AIM: This study was a systematic review of toxic substance-induced animal models of AD using the Morris Water Maze method in determining hippocampal-related memory impairment. Our aim was reviewing the methods of AD induction using toxic substances in laboratory rodents and evaluating the report of the AD biomarkers reported in the models. METHODS: Data were obtained from articles in the PubMed database, then compiled, categorized, and analyzed. Eighty studies published in the past 5 years were included for analysis. RESULTS AND DISCUSSION: The most widely used method was intracerebroventricular injection of amyloid-β _substances. However, some less technically challenging techniques using oral or intraperitoneal administration of other toxic substances also produce successful models. Instead of hippocampal neurodegeneration, many studies detected biomarkers of the AD pathological process while some reported inflammation, oxidative stress, neurotrophic factors, and changes of cholinergic activity. Female animals were underrepresented despite a high incidence of AD in women. CONCLUSION: Toxic substances may be used to develop AD animal models characterized with appropriate AD pathological markers. Characterization of methods with the most easy-handling techniques and more studies in female animal models should be encouraged.

show abstract

miR‑132 improves the cognitive function of rats with Alzheimer's disease by inhibiting the MAPK1 signal pathway

Cited by 49 publications

References 43 publications

Alzheimer’s Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target

Alzheimer’s Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target

The Eminent Role of microRNAs in the Pathogenesis of Alzheimer's Disease

Toxic Substance-induced Hippocampal Neurodegeneration in Rodents as Model of Alzheimer’s Dementia

Contact Info

Product

Resources

About